Hai cercato la traduzione di emetogenic da Inglese a Maltese

highly emetogenic chemotherapy regimen
kors ta' kimoterapija ferm emetoġenika

11 highly emetogenic chemotherapy regimen
11 fi studji kliniċi, il- korsijiet li ġejjin intużaw għall- prevenzjoni ta 'nawseja u rimettar assoċjati ma' kimoterapija tal- kanċer emetoġenika:

highly emetogenic chemotherapy (hec) study
studju dwar kimoterapiji kontra l-kanċer emetoġenika b’mod qawwi (highly emetogenic chemotherapy (hec))

recent guidance has updated these regimens to highly emetogenic.
gwida riċenti aġġornat dawn il-korsijiet bħala li huma emetoġeniċi b’mod qawwi.

prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
prevenzjoni ta ’ nawsja u rimettar assoċjati ma ’ kimoterapija tal- kanċer moderatament emetoġenika.

percent of patients receiving moderately emetogenic chemotherapy who remain emesis free over time
perċentwal ta’ pazjenti li jkunu qed jirċievu kimoterapija emetoġenika b’mod moderat li jibqgħu ma jirremettux mal-ħin

prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.
prevenzjoni ta 'nawseja u rimettar assoċjati ma' kimoterapija tal- kanċer ferm emetoġenika bbażata fuq cisplatin fl- adulti.

prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
prevenzjoni ta’ dardir u rimettar akut u li jseħħ wara ċertu żmien, assoċjati ma’ kimoterapija kontra l-kanċer moderatament emetoġenika.

a second main study looked at the benefits of akynzeo in patients undergoing moderately emetogenic chemotherapy.
studju ewlieni ieħor ħares lejn il-benefiċċji ta' akynzeo f'pazjenti li saritilhom kimoterapija moderatament emetoġenika.

figure 1 percent of patients receiving highly emetogenic chemotherapy who remain emesis free over time – cycle 1
figura 1 perċentwal ta 'pazjenti li kienu qed jirċievu kimoterapija ferm emetoġenika li jibqgħu mingħajr emesi maż- Żmien – Ċiklu 1

32 table 1 percent of patients receiving highly emetogenic chemotherapy responding by treatment group and phase — cycle 1
tabella 1 perċentwal ta 'pazjenti li jirċievu kienu qed jirċievu kimoterapija ferm emetoġenika li jirrispondu skond il- grupp u fażi ta' trattament — Ċiklu 1

prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy.
prevenzjoni ta ’ nawsja u rimettar akuti jew ittardjati assoċjati ma ’ kimoterapija tal- kanċer emetoġenika ħafna ibbażata fuq cisplatin.

palonosetron was non-inferior versus the comparators in the acute phase of emesis both in moderately and highly emetogenic setting.
palonosetron ma kienx inferjuri mqabbel mal-komparaturi fil-fażi akuta ta’ l-emesi, f’ċirkustanzi ematoġeniċi kemm moderati u kemm qawwija.

patients who are being treated with moderately or highly emetogenic chemotherapy may still experience vomiting despite treatment with antiemetic therapy, including sancuso.
pazjenti li jkunu qed jiġu kkurati b’kimoterapija emetoġenika moderata jew qawwija ħafna jistgħu xorta waħda jkollhom ir-rimettar minkejja terapija b’mediċini kontra d-dardir u r-rimettar (antiemetiċi), li jinkludu sancuso.

the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
prevenzjoni ta’ dardir u rimettar akut assoċjat ma’ kimoterapija tal-kanċer li hi emetoġenika b’mod qawwi, prevenzjoni ta’ dardir u rimettar marbut ma’ kimoterapija tal-kanċer li hi moderatament emetoġenika.

in a multicentre, randomised, double-blind active control clinical trial of 635 patients set to receive moderately emetogenic cancer chemotherapy.
fi prova klinika multiċentrika, li fiha l-individwi ntgħażlu b’mod każwali, double-blind u b’kontroll attiv, li saret fuq 635 pazjent li kienu qed jingħataw kimoterapija moderatament emetoġenika kontra l- kanċer.

emetogenic chemotherapies administered included doxorubicin, cyclophosphamide (<1500 mg/m2), ifosfamide, cisplatin, dactinomycin, carboplatin, and daunorubicin.
kimoterapiji emetoġeniċi mogħtija kienu jinkludu doxorubicin, cyclophosphamide (<1500 mg/m2), ifosfamide, cisplatin, dactinomycin, carboplatin, u daunorubicin.

in two randomised, double-blind studies with a total of 1,132 patients receiving moderately emetogenic chemotherapy that included cisplatin ≤50 mg/m2, carboplatin, cyclophosphamide
f’żewġ studji randomised, double-blind b’total ta’ 1,132 pazjent li kienu qed jirċievu kimoterapija moderatament emetoġenika li kienet tinkludi cisplatin ≤50 mg/m2, carboplatin, cyclophosphamide